XFOR | X4 Pharmaceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	3.83 - 4.81
52 Week Range	3.83 - 36.00
Beta	0.82
Implied Volatility	407.02%
IV Rank	34.40%
Day's Volume	435,697
Average Volume	76,085
Shares Outstanding	5,788,740
Market Cap	24,949,469
Sector	Healthcare
Industry	Biotechnology
IPO Date	2017-11-16

Valuation
Profitability
Growth
Health
P/E Ratio	-0.76
Forward P/E Ratio	N/A
EPS	-5.70
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	127
Country	USA
Website	XFOR

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002, a CXCR4 antagonist for the treatment of brain cancers; and X4P-003, a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2010 and is headquartered in Boston, Massachusetts.

XFOR's peers: ABEO, ABOS, ABSI, ACHV, ADMA, AFMD, AGEN, AKBA, ALDX, ALT, ALZN, AMLX, ANNX, APLS, APLT, ARQT, ATRA, AUTL, BBIO, BCLI, BCRX, BCTX, BHVN, BIVI, BLRX, BPMC, BTAI, CNTX, CPRX, CRBP, CRIS, CRVS, CTXR, CUE, CYCN, CYTK, DAWN, DMAC, DTIL, ELDN, ETNB, EXEL, EYPT, GERN, GLSI, GNPX, GOSS, HOOK, HRTX, IBRX, IDYA, INKT, INVA, INZY, KPTI, LPTX, LQDA, LXRX, MDGL, MESO, MIRM, MIST, MREO, MRSN, NERV, OCUL, ONCY, ORMP, OTLK, PDSB, PHAT, PLX, PRTG, PTGX, PYXS, QURE, RARE, RCUS, RIGL, RXRX, SANA, SLNO, SPRB, TCRX, TERN, TGTX, TSHA, VCEL, VKTX, VRNA, VYGR, WVE, XBIT, XERS, EFTR, ELEV, HEPA, ERNA, GPCR

*Chart delayed

Analyzing fundamentals for XFOR we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see XFOR Fundamentals page.

Watching at XFOR technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on XFOR Technicals page.